Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.44 |
| ▸ | KLK3 | P07288 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004863 | 0.86 | CTNNB1 (0.59) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL27775517 | 0.84 | CTNNB1 (0.57) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL27775537 | 0.84 | CTNNB1 (0.57) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL3492945 | 0.84 | TAS1R3 (0.54) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL27775515 | 0.83 | CTNNB1 (0.56) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL21129477 | 0.82 | TAS1R3 (0.56) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| Ammonia Solution, Strong SCHEMBL20898199 | 0.82 | TAS1R3 (0.52) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL5591686 | 0.82 | DYRK1A (0.46) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL11989349 | 0.78 | TAS1R3 (0.59) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL12173891 | 0.78 | TAS1R3 (0.59) | TAS1R3TAS1R1NAMPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528797-B2 | Heterocyclic compounds for medical treatment | C4 THERAPEUTICS, INC. | 2026-01-20 | — | — | US | disclosed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-115884970-A | Aryl formamide compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022063205-A1 | ARYL FORMAMIDE COMPOUND, PREPARATION METHOD FOR SAME, AND MEDICINAL USES THEREOF | 中国医药研究开发中心有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | FIRMENICH INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3394052-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017108282-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2017-06-29 | — | — | WO | disclosed |
| CN-1524078-A | Antagonists of mcp-1 function and methods of use thereof | ̩ | 2004-08-25 | — | — | CN | disclosed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | disclosed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0931074-A1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | Takeda Chemical Industries, Ltd. (JP) | 1999-07-28 | — | — | EP | disclosed |
| CN-1039415-C | Heterocyclic compounds | ZENECA LTD (GB) | 1998-08-05 | — | — | CN | disclosed |
| WO-1998009958-A1 | CONDENSED 4,5,6,7-TETRAHYDROBENZO[C]THIOPHENES AS ENHANCER FOR CELL DIFFERENTIATION INDUCTION FACTOR ACTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-12 | — | — | WO | disclosed |
| CN-1094400-A | Heterogeneous ring compound | ZENECA LTD (GB) | 1994-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | TAS1R3 4848/4885TAS1R1 4828/4885NAMPT 3318/4885 |
| US-12528797-B2 | Heterocyclic compounds for medical treatment | CRBN, CUL2, ADRM1 | TAS1R3 4529/4885TAS1R1 4266/4885NAMPT 4798/4885 |
| US-20030092728-A1 | Antagonists of MCP-1 function and methods of use thereof | CCL11, CCR1, CCR2 | TAS1R3 1815/4885TAS1R1 890/4885NAMPT 1668/4885 |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | TAS1R3 2431/4885TAS1R1 1490/4885NAMPT 2009/4885 |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | TAS1R3 3520/4885TAS1R1 3465/4885NAMPT 802/4885 |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | TAS2R40, TAS1R2, TAS1R1 | TAS1R3 5/4885TAS1R1 3/4885NAMPT 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.